News | 17 May 2023
Farxiga’s expanded approval highlights potential to differentiate in HF space, says GlobalData
Farxiga is expected to have such a strong influence on the market due to the impressive results
Farxiga is expected to have such a strong influence on the market due to the impressive results
The facility will have a capacity to manufacture upto 3 million tubes monthly
The company has reported total income of Rs. 149.78 crores during the period ended March 31, 2023
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023
Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
The Awards recognizes standout digital health & medical technology products and companies
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Subscribe To Our Newsletter & Stay Updated
